- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04826874
Affect Labeling - Experimental Evaluation and Behavioral Intervention (AL_ER)
The overall aim of this project is to better understand the emotion regulating effect of labeling emotions (affecting labeling, AL) for individuals with self-perceived emotional regulation difficulties from both a clinical population and a non-clinical population, by using both self-assessment and psychophysiological testing of emotional activation. The main part of the project includes a brief intervention aiming to test the emotion-regulating effect of a short behavioral intervention to learn and practice AL. This two-week intervention, aims to improve the ability to regulate emotions, and to assess the benefits of emotion regulation strategies for individuals with and without a clinical diagnosis, but with self-perceived difficulties in emotion regulation.
The second part of this study aims to conceptually replicate a previous basic research study on AL and its emotion-regulating effect in a experimental laboratory setting and to extend that replication to include a clinical group. The replication contributes to an indepth understanding of AL as an implicit emotion regulation strategy in the short term, i.e. as a strategy used directly in the emotionally charged situation, and expands that knowledge to also include the effect in individuals with a clinical diagnosis. Also, it provides the opportunity to evaluate the effect of the two week AL behavioral intervention using psychophysiological testing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Main study: AFFECT LABELING - DAILY EXERCISE IN PUTTING WORDS ON EMOTIONS DESIGN AND PROCEDURE This clinical study is a randomized, wait-list controlled design with repeated measurements. Participants are randomized at inclusion between being directly offered a 14-day course to train AL and waiting two weeks before beginning the intervention. Participants are blind to this randomization and do not know that they are in the waitlist condition, in order to avoid nocebo effects. The randomization is done 1: 1, and stratified by clinical categorization (participants with or without a psychiatric diagnosis).
The course is given via a secure web platform (BASS4) in which the participant also makes all their assessments, and interacts with the study material and their course leader (clinical psychologist or master level psychology students).
Intervention - web course in affect labeling The intervention is given as a two week internet-delivered course in using AL with the guidance of a course leader (licensed psychologist or psychologist assistant under supervision). The course is divided into two modules where module 1 contains a) Psychoeducation about different emotions and its function, b) Information about AL and its potential emotion-regulating effect, c) Instruction on how to use AL in everyday life and d) Planning of daily short exercises in naming emotions. Daily registration with multiple choice answers is introduced to help the practice of AL. All assessments are web-based and reminders are sent to the participants' cellphone. The course leader is active in providing feedback on the exercises and planning.
Module 2 is largely a continuation of module 1 where any obstacles and other difficulties are discussed in order to increase the chance of active practice in AL, and continued daily practice. Module 3 is a brief summary of what has been taught and is made available to the participant after post-assessment.
Laboratory sub-study: Participants will also participate in a laboratory-based study where the emotion regulating effect of AL will be compared with distraction or passive viewing while being exposed to emotionally provocative visual stimuli. Participants are exposed to 3 blocks of 8 images and questions about the images ("trials") with equal numbers of negative and neutral valence in three conditions: instruction to "Watch", instruction to use AL and instruction to use Distraction. The instructions and pictures are given in a randomized, balanced order. Before each block, a 3-second instruction is displayed that indicates whether the participant should use "Watch", "AL" or "Distraction" for all 8 images in the block.
All participants will carry out the laboratory sub-study on two occasions: before and after the 14 day period it takes for the individuals who directly receives the web-based course in AL to complete it.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17177
- Karolinska Institutet, department of clinical neuroscience
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Sufficient skills in Swedish to be able to fill in self-assessment questionnaires.
- State at least a 3 (or higher) out of 10 regarding everyday difficulties with emotion regulation according to a scale created for this purpose: Do you feel that you currently have problems regulating your emotions? Circle the number that is best for you "(0 no problems at all, 10 Very severe problems.
- Answer "Yes, very much" or "Yes" to the following question: "Would you like to learn to regulate/manage your emotions better?" with the options "Yes, very much / Yes / Maybe, but doubtful if it is worth the effort, does not fit right now / No".
Exclusion Criteria:
- Psychiatric or somatic status that may prevent the participant from completing the experiment or require some form of care intervention the participant does not already undergo.
- Medium to high risk of suicide.
- Moderate to severe self-harming behavior.
- Blood phobia.
- Regular medication with benzodiazepines (including sleep medication, ex Stilnoct).
- Ongoing treatment with emotion regulation elements.
To be part of the clinical group, the participant must state a diagnosis established by a medical professional in the last 5 years, which involves clinical difficulties with emotion regulation such as binge eating disorder, emotional instability, generalized anxiety, depression, social anxiety or ADHD, and does not plan to start, change or discontinue any psychosocial or pharmacological treatment within the next 4 weeks. The non-clinical group must not have been diagnosed or treated for mental illness in the last 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Affect Labeling_direct
Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling
|
Short behavioral intervention teaching affect labeling
|
|
No Intervention: Wait-list
Randomized to a two-week wait-list control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in The Difficulties in Emotion Regulation Scale, DERS (Gratz & Roemer, 2004)
Time Frame: At day 1 and at day 14 (+/- 5 days)
|
Min 36, Max 180.
Higher scores represents worse outcome
|
At day 1 and at day 14 (+/- 5 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer, & Williams, 2001)
Time Frame: At baseline and day 14 (+/- 5 days)
|
Min 0, Max 27.
Higher scores represents worse outcome
|
At baseline and day 14 (+/- 5 days)
|
|
The Generalized Anxiety Disorder 7-item Scale (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006).
Time Frame: At baseline and day 14 (+/- 5 days)
|
Min 0, Max 21.
Higher scores represents worse outcome
|
At baseline and day 14 (+/- 5 days)
|
|
The Emotion Regulation Questionnaire (ERQ; Gross & John, 2003)
Time Frame: At day 1 and day 14 (+/- 5 days)
|
Two sub scales: Cognitive reappraisal: Min 6 Max 42.
Higher scores represents higher use of reappraisal.
Suppression: Min 4 Max 28.
Higher scores represents more use of suppression.
|
At day 1 and day 14 (+/- 5 days)
|
|
The Toronto Alexithymia Scale (TAS-20; Bagby et al., 1994).
Time Frame: At baseline and day 14 (+/- 5 days)
|
Min 20, Max 100.
Higher scores represents worse outcome
|
At baseline and day 14 (+/- 5 days)
|
|
The Ruminative responses scale - Brooding and Reflection (RRS-BR; Treynor et al., 2003, Cronwall, 2019).
Time Frame: At baseline and day 14 (+/- 5 days)
|
Min 10 Max 40.
Higher scores represents worse outcome
|
At baseline and day 14 (+/- 5 days)
|
|
the Client Satisfaction Questionnaire, 8 item (CSQ-8; Attkisson & Zwick, 1982).
Time Frame: At day 14 (+/- 5 days)
|
Min 8 Max 32 Higher scores represents better outcome
|
At day 14 (+/- 5 days)
|
|
Levels of expected emotional upset
Time Frame: At day 1 and day 14 (+/- 5 days)
|
9-degree Likert scale.
Min 1 (Not upset at all) Max 9 (Very upset).
|
At day 1 and day 14 (+/- 5 days)
|
|
Change in Heart Rate Variability (HRV) (micro-Siemens (μS)) averaged over a 5 sec time window, and repeated 8 times per condition, ie. 8*5 seconds repeated 3 times.
Time Frame: At day 1 and at day 14 (+/- 5 days)
|
Heart Rate Variability is a measure which indicates the variation in your heartbeats within a specific timeframe.
|
At day 1 and at day 14 (+/- 5 days)
|
|
Change in The Affect Labeling Questionnaire, ALQ (Sahi, et al. (in prep)
Time Frame: At day 1 and at day 14 (+/- 5 days)
|
Min 12, Max 60.
Higher scores represents better outcome
|
At day 1 and at day 14 (+/- 5 days)
|
|
Change in Experienced emotional upset (Time frame: averaged over a 5 sec time window, repeated 24 times during the experiment)
Time Frame: At day 1 and day 14 (+/- 5 days)
|
9-degree Likert scale.
Min 1 (Not upset at all) Max 9 (Very upset).
|
At day 1 and day 14 (+/- 5 days)
|
|
Change in skin conductance response between three different emotion regulation conditions
Time Frame: 3*8*5 seconds at Day 1 and at Day 14 (+/-5 days)
|
changes in skin conductance, mean (micro-Siemens (μS)) between the different emotion regulation conditions
|
3*8*5 seconds at Day 1 and at Day 14 (+/-5 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hanna Sahlin, Med Dr, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2020-06427
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emotional Dysregulation
-
Massachusetts General HospitalMassachusetts Institute of TechnologyNot yet recruitingEmotional DysregulationUnited States
-
Consorci Sanitari del MaresmeUniversity Ramon LlullNot yet recruitingEmotional Dysregulation
-
Northwestern UniversityCompletedEmotional DysregulationUnited States
-
Neuromotion LabsNational Institute of Mental Health (NIMH); Magellan HealthcareCompleted
-
Soroka University Medical CenterUnknownEmotional Dysregulation | Dialectical Behavioral TherapyIsrael
-
University Hospital, Strasbourg, FranceNot yet recruitingEmotional Dysregulation | Addiction DisordersFrance
-
Fundación Pública Andaluza para la gestión de la...Instituto de Salud Carlos III; Hospital Universitario Virgen del RocioNot yet recruitingNeurodevelopmental Disorders | Irritability | Distress, Emotional | Emotional Dysregulation | Impulsivity | Distress, PsychologicalSpain
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompletedEmotional DysregulationItaly
-
University of Texas Southwestern Medical CenterNot yet recruitingAdolescent | Depression | Emotional Dysregulation | Family Relationship | HRVUnited States
-
Universiti Utara MalaysiaMinistry of Education, MalaysiaNot yet recruitingEmotional Dysregulation | Non-Suicidal Self-InjuryMalaysia
Clinical Trials on Affect labeling
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Max Planck Institute for Human Cognitive and Brain...European Research CouncilCompleted
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertensionUnited States
-
University of California, Los AngelesSouthern Methodist UniversityCompleted
-
University of Colorado, BoulderNational Institute of Mental Health (NIMH)CompletedPhysical Activity | Affect
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruitingNicotine Labeling for E-cigarettesUnited States
-
University of California, Los AngelesSouthern Methodist UniversityCompleted
-
University of California, Los AngelesSouthern Methodist UniversityCompleted
-
Northwestern UniversityEmory University; Louisiana State University Health Sciences Center ShreveportCompleted
-
Xuanwu Hospital, BeijingRecruiting